NCT00991419CompletedPhase 2
A Phase II, Open Label, Non-Randomized Study of [18F]AZD4694 to Compare PET Measurements of Fibrillar Amyloid Burden Obtained Using Difference Scanning Parameters, Reference Region Procedures and to Assess Test-retest Reliability in Patients With AD & HV
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- PET Measurements
Study Overview
Brief Summary
The purpose of this study is to compare PET measurements of fibrillar amyloid burden using [18F]AZD4694.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Diagnostic
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Male or female, of any race or/ethnicity
- •ECG, vital signs, and clinical laboratory values are within normal limits at enrollment or deemed not clinically significant by the physician
Exclusion Criteria
- •Significant recent (within 6 months) history of neurological (including stroke) or psychiatric disorder or substance abuse
- •Participated in a PET study within the last 12 months
- •Pregnancy or lactation
Arms & Interventions
A
Experimental
[18F]4694
Intervention: [18F]AZD4694 (Drug)
Outcomes
Primary Outcomes
PET Measurements
Time Frame: Day 1 and Day 7
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission TomographyMultiple MyelomaNCT03779815Ulsan University Hospital14
Completed
Phase 2
Florbetapir F 18 PET Imaging of Beta-amyloid in Parkinson's Disease PatientsParkinson's DiseaseNCT00857532Avid Radiopharmaceuticals31
Completed
Phase 3
Phase III Study of the Correlation Between Florbetapir F18 PET Imaging and Amyloid Pathology in the BrainAlzheimer's DiseaseNCT00857415Avid Radiopharmaceuticals226
Recruiting
Not Applicable
Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-FluselenamylAlzheimer DiseaseNCT06439992Washington University School of Medicine60
Completed
Phase 1
Plasma P-tau2017 and Quantitative Amyloid PET ImagingAlzheimer DiseaseNCT05164536Invicro140